The Absolute Effect

Oncology Trial Evidence Index

The Absolute Effect translates oncology trial results into absolute benefit, harm, NNT and NNH where defensible. Each linked trial page is a permanent, crawlable evidence page.

New evidence pages · 26 October 2026

Twenty newly integrated oncology studies across medical, surgical, radiation, biomarker and imaging evidence. Each page includes population, treatment comparison, outcomes, harms and primary-source links. Browser-rendered QA and full independent clinical freshness review remain pending.

Evidence pages

  • NSABP B-17 · Breast cancer · DCIS / breast-conserving surgery
  • NSABP B-24 · Breast cancer · DCIS / endocrine therapy
  • RTOG 9408 · Prostate cancer · localized intermediate-risk intensification
  • MRC RT01 · Prostate cancer · localized dose escalation
  • SWOG 9346 · Prostate cancer · metastatic ADT strategy
  • AVOREN · Renal cell carcinoma · metastatic first-line therapy
  • PISCES · Renal cell carcinoma · patient preference / QoL
  • IMvigor211 · Bladder cancer · platinum-refractory metastatic disease
  • CheckMate 275 · Bladder cancer · platinum-refractory metastatic disease
  • Daugaard stage-I NSGCT surveillance cohort · Germ-cell tumours · stage I nonseminoma
  • NSABP B-21 · breast-cancer · RT omission / small node-negative tumours
  • TROG 03.04 RADAR · prostate-cancer · ADT duration
  • NRG/RTOG 0521 · prostate-cancer · high-risk localized systemic intensification
  • GETUG-AFU 17 · prostate-cancer · post-prostatectomy adjuvant vs early salvage
  • CheckMate 025 · renal-cell-carcinoma · previously treated metastatic RCC
  • AXIS · renal-cell-carcinoma · previously treated metastatic RCC
  • Pagliaro TIP · penile-cancer · bulky regional neoadjuvant therapy
  • CUETO 98013 · bladder-cancer · high-risk NMIBC / BCG maintenance
  • TRISST / MRC TE24 · germ-cell-tumours · stage I seminoma surveillance / imaging
  • MRC TE23 · germ-cell-tumours · poor-prognosis metastatic disease
  • RTOG 0617 · Non-Small Cell Lung Cancer · Radiation · Stage III · Definitive Chemoradiation
  • MRC CR07 / NCIC-CTG C016 · Rectal Cancer · Radiation · Locally Advanced · Preoperative RT
  • Dutch TME Trial · Rectal Cancer · Surgical · Locally Advanced · Total Mesorectal Excision
  • PRODIGE 4/ACCORD 11 · Pancreatic Cancer · Medical · Metastatic · First-line
  • ABC-02 · Biliary Tract Cancer · Medical · Advanced/Metastatic · First-line
  • SHARP · Hepatocellular Carcinoma · Medical · Advanced/Unresectable · First-line
  • EORTC 26951 / RTOG 9402 · Neuro-Oncology · Medical · Grade 3 Oligodendroglial Tumour · Adjuvant
  • IDEA Collaboration · Colon Cancer · Medical · Stage III · Adjuvant Duration
  • ESPAC-4 · Pancreatic Cancer · Medical · Resected · Adjuvant
  • MRC OE02 · Esophageal Cancer · Medical · Locally Advanced Resectable · Neoadjuvant

    • ← Return to The Absolute Effect

    New evidence added · 21 October 2026

    Ten new canonical trial pages added to the evidence atlas.

    New evidence added · 22 October 2026

    Ten canonical trial pages were added after the second-pass duplicate audit.

    Radiation oncology reference · Lung SABR protocols

    Trial-by-trial definitions of peripheral, central and ultracentral lesions, fractionation schedules, and reported OAR constraints. Exact protocol limits are flagged where full-source verification is still required.

    New evidence added · 23 October 2026

    Four additional trial pages plus a protocol-focused lung SABR reference.

    New evidence added · 23 October 2026 — additional batch

    Ten new canonical trial pages added after a second duplicate check. POUT was already present and was retained without duplication; PEARLS / KEYNOTE-091 was used as the replacement.